Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy

Ophthalmology

Volumn 112, Issue 5, 2005, Pages 771-779

  Jabs, Douglas A ^a,b,f   Holbrook, Janet T ^b   Van Natta, Mark L ^b   Clark, Rebecca ^c   Jacobson, Mark A ^d   Kempen, John H ^a,b   Murphy, Robert L ^e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIVIRUS AGENT; CD4 ANTIGEN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; CELL COUNT; FEMALE; FUNGAL MENINGITIS; HEMOGLOBIN DETERMINATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OPHTHALMOLOGY; PRIORITY JOURNAL; PROGNOSIS; RETINITIS; RISK FACTOR; T LYMPHOCYTE; VIROLOGY; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CYTOMEGALOVIRUS RETINITIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RISK FACTORS; VIRAL LOAD;

EID: 18244378223     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2004.10.049     Document Type: Article

References (55)

1. F.J. Palella Jr, K.M. Delaney, A.C. Moorman HIV Outpatient Study Investigators Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection N Engl J Med 338 1998 853 860
2. E.L. Murphy, A.C. Collier, L.A. Kalish Viral Activation Transfusion Study Investigators Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease Ann Intern Med 135 2001 17 26
3. HIV AIDS Surveillance Report 14 2002 1 22 Available at: http://www.cdc.gov/hiv/stats/hasr1402/2002SurveillanceReport.pdf. Accessed January 27, 2005
4. K.V. Komanduri, M.N. Viswanathan, E.D. Wieder Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1 Nat Med 4 1998 953 956
5. R. Detels, P. Tarwater, J.P. Phair Multicenter AIDS Cohort Study Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis AIDS 15 2001 347 355
6. D.A. Jabs, G. Bolton, J.P. Dunn, A.G. Palestine Discontinuing anti-cytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy Am J Ophthalmol 126 1998 817 822
7. C. Tural, J. Romeu, G. Sirera Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients J Infect Dis 177 1998 1080 1083
8. S.M. Whitcup, E. Fortin, A.S. Lindblad Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis JAMA 282 1999 1633 1637
9. F.J. Torriani, W.R. Freeman, J.C. Macdonald CMV retinitis recurs after stopping treatment in virological and immunological failure of potent antiretroviral therapy AIDS 14 2000 173 180
10. J.E. Kaplan, H. Masur, K.K. Holmes Guidelines for the prevention of opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Disease Society of America MMWR Recomm Rep 51 RR-8 2002 1 52 Available at: http://www.cdc.gov/mmwr/preview/ mmwrhtml/rr5108a1.htm. Accessed January 27, 2005
11. G.M. Lucas, R.E. Chaisson, R.D. Moore Highly active antiretroviral therapy in a large urban clinic risk factors for virologic failure and adverse drug reactions Ann Int Med 131 1999 81 87
12. D.A. Jabs, J.G. Bartlett AIDS and ophthalmology a period of transition Am J Ophthalmol 124 1997 227 233
13. M.A. Jacobson, H. Stanley, C. Holtzer Natural history and outcome of new AIDS-related cytomegalovirus retinitis diagnosed in the era of highly active antiretroviral therapy Clin Infect Dis 30 2000 231 233
14. D.A. Jabs, M. Van Natta, J.H. Kempen Studies of Ocular Complications of AIDS Research Group Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy Am J Ophthalmol 133 2002 48 61
15. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults MMWR Recomm Rep 41 RR-17 1992 1 19 Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/ 00018871.htm. Accessed January 27, 2005
16. D.A. Karnofsky, W.H. Abelmann, L.F. Craver, J.H. Burchenal The use of the nitrogen mustards in the palliative treatment of carcinoma Cancer 1 1948 634 656
17. D.A. Jabs, M. Forman, C. Enger, J.B. Jackson Cytomegalovirus Retinitis and Viral Resistance Study Group Comparison of cytomegalovirus loads in plasma and leukocytes of patients with cytomegalovirus retinitis J Clin Microbiol 37 1999 1431 1435
18. D.A. Jabs Ocular manifestations of HIV infection Trans Am Ophthalmol Soc 93 1995 623 683
19. D.R. Cox Regression models and life-tables J R Stat Soc Ser B Methods 34 1972 187 220
20. P.M. Tarwater, J. Mellors, M.E. Gore Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts Am J Epidemiol 154 2001 675 681
21. J.L. Schafer Multiple imputation a primer Stat Methods Med Res 8 1999 3 15
22. SAS/STAT User's Guide. Version 8.0 1999 SAS Institute Cary, NC
23. Stata [computer program]. Release 7.0 2001 Stata Corp College Station, TX
24. D.R. Hoover, Y. Peng, A. Saah Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression Arch Ophthalmol 114 1996 821 827
25. B.D. Kuppermann, J.G. Petty, D.D. Richman Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome Am J Ophthalmol 115 1993 575 582
26. J.W. Mellors, C.R. Rinaldo Jr, P. Gupta Prognosis in HIV-1 infection predicted by the quantity of virus in plasma Science 272 1996 1167 1170
27. V. Miller, A. Mocroft, P. Reiss EuroSIDA Study Group Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression results from the EuroSIDA study Ann Intern Med 130 1999 570 577
28. S. Grabar, V. Le Moing, C. Goujard Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy Ann Intern Med 133 2000 401 410
29. A.N. Phillips, S. Staszewski, R. Weber Swiss HIV Cohort Study, Frankfurt HIV Clinic Cohort, EuroSIDA Study Group HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load JAMA 286 2001 2560 2567
30. R.D. Moore, R.E. Chaisson Natural history of opportunistic disease in an HIV-infected urban clinical cohort Ann Intern Med 124 1996 633 642
31. J.E. Gallant, R.D. Moore, D.D. Richman Zidovudine Epidemiology Study Group Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine J Infect Dis 166 1992 1223 1227
32. P. Pertel, R.E. Hirschtick, J. Phair Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus J Acquir Immune Defic Syndr 5 1992 1069 1074
33. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis N Engl J Med 326 1992 213 220
34. Studies of Ocular Complications of AIDS, AIDS Clinical Trials Group Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS Arch Ophthalmol 114 1996 23 33
35. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group MSL-109 adjuvant therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. The Monoclonal Antibody Cytomegalovirus Retinitis Trial Arch Ophthalmol 115 1997 1528 1536
36. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome the Ganciclovir Cidofovir Retinitis Trial Am J Ophthalmol 131 2001 457 467
37. J.C. Walsh, C.D. Jones, E.A. Barnes Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors AIDS 12 1998 613 618
38. J.L. Casado, M.J. Perez-Elias, P. Marti-Belda Improved outcome of cytomegalovirus retinitis in AIDS patients after introduction of protease inhibitors J Acquir Immune Defic Syndr Hum Retroviral 19 1998 130 134
39. J.H. Kempen, D.A. Jabs, L.A. Wilson Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome Clin Infect Dis 37 2003 1365 1373
40. R.S. Hogg, B. Yip, K.J. Chan Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy JAMA 286 2001 2568 2577
41. M. Shinkai, S.A. Bozzette, W. Powderly Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease J Infect Dis 175 1997 302 308
42. S.A. Spector, K. Hsia, M. Crager Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS J Virol 73 1999 7027 7030
43. M.F. Para, L.A. Kalish, A.C. Collier Viral Activation Transfusion Study Group Correlates of change in cytomegalovirus viremia in patients with advanced human immunodeficiency virus infection who require transfusion J Infect Dis 183 2001 1673 1677
44. C.E. O'Sullivan, W.L. Drew, D.J. McMullen Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy J Infect Dis 180 1999 847 849
45. J. Deayton, A. Mocroft, P. Wilson Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy AIDS 13 1999 1203 1206
46. R. Lamarca, J. Alsonso, G. Gomez, A. Munoz Left-truncated data with age as time scale an alternative survival analysis in the elderly population J Gerontol A Biol Sci Med Sci 53 1998 M337 M343
47. J.L. Kelsey, A.S. Whittemore, A.S. Evans, W.D. Thompson Methods in Observational Epidemiology 2nd ed. 1996 Oxford University Press New York 105 107 Monographs in Epidemiology and Biostatistics. Vol. 26
48. J.S. Pepose, G.N. Holland, M.S. Nestor Acquired immune deficiency syndrome. Pathogenic mechanisms of ocular disease Ophthalmology 92 1985 472 484
49. M.G. Davis, S.C. Kenney, J. Kamine Immediate-early gene region of human cytomegalovirus trans-activates the promoter of human immunodeficiency virus Proc Natl Acad Sci U S A 84 1987 8642 8646
50. P.R. Skolnik, B.R. Koslof, M.S. Hirsch Bidirectional interactions between human immunodeficiency virus type 1 and cytomegalovirus J Infect Dis 157 1988 508 514
51. A. Kovacs, M. Schluchter, K. Easley Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women N Engl J Med 341 1999 77 84
52. A. Webster, C.A. Lee, D.G. Cook Cytomegalovirus infection and progression towards AIDS in haemophiliacs with human immunodeficiency virus infection Lancet 2 1989 63 66
53. C.A. Sabin, A.N. Phillips, C.A. Lee The effect of CMV infection on progression of human immunodeficiency virus disease in a cohort of haemophilic men followed for up to 13 years from seroconversion Epidemiol Infect 114 1995 361 372
54. S.V. Kotenko, S. Saccani, L.S. Izotova Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10) Proc Nat Acad Sci U S A 97 2000 1695 1700
55. J.V. Spencer, K.M. Lockridge, P.A. Barry Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10 J Virol 76 2002 1285 1292